Document is current

Article History

Received: 8 August 2022

Accepted: 12 April 2023

First Online: 24 April 2023

Declarations

:

: The study was approved by a central ethics review board and by local institutional boards in each participating center (ExternalRef removed, protocol number CAAE 45781015.8.1001.5259). All participants granted informed consent; all procedures were in accordance with the ethical standards of the Brazilian National Research Committee and with the 1964 Helsinki declaration and its later amendments.

: All participants granted informed consent for publication.

: CPA reports personal fees and/or non-financial support from Pfizer, AbbVie, AstraZeneca, Janssen, Bristol-Myers Squibb, Roche, Novartis and UCB, outside the submitted work. APMG reports personal support and consulting fees from Pfizer. ABVS reports support for international medical events from AbbVie and Janssen. MBB reports having participated in clinical and/or experimental studies related to this work and sponsored by Roche and having delivered speeches at events related to this work and sponsored by AbbVie and Pfizer. PLJ reports support for international congresses from Bristol-Myers Squibb, UCB; and consulting fees from Pfizer; RDNG reports consulting fees, speaking fees and support for international congresses from Roche, Pfizer, Bristol-Myers Squibb, UCB, Eli-Lilly, AbbVie, Abbott and EMS. SCR reports consulting and speaking fees from AbbVie, Janssen, Pfizer, Roche and UCB. MFBRG reports speaking fees and support for congresses from AbbVie, Bristol-Myers Squibb, Janssen, Novartis, Pfizer, Roche and UCB. KRB reports speaking fees and support for international congresses from Roche, Pfizer, Bristol-Myers Squibb, AbbVie and Janssen. MFLCS reports no financial disclosures. IAP reports consulting fees, speaking fees and support for internationals congresses from Roche, Pfizer, UCB Pharma, Eli-Lilly, AbbVie and Janssen. CVB reports having participated in clinical and/or experimental studies related to this work and sponsored by AbbVie, BMS, Janssen, Pfizer and Roche; having received personal or institutional support from AbbVie, BMS, Janssen, Pfizer and Roche; having delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer and Roche. LMHM reports personal or institutional support from AbbVie, Janssen, Pfizer and Roche; and having delivered speeches at events related to this work and sponsored by AbbVie, Janssen, Pfizer, Roche and UCB. LSN reports no financial disclosures. GRCP reports consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Glaxosmithkline, Janssen, Pfizer, Sanofi Genzyme and Roche.